The centers perform a combined 60,000 cataract procedures annually and will use Dexycu in their surgical protocols for treating ocular inflammation. EyePoint President and CEO Nancy Lurker said the company will work with Vision Center Network to broaden the drug’s U.S. adoption rate and help treat inflammation in patients.
More articles on surgery centers:
5 ways ASCs can manage orthopedic costs
US inching closer to financial crisis, CBO estimates say
Anthem concentrating on risk-based arrangements, appropriate care settings in 2020
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.